Member Info for Mars1

Interesting that there have been a lot of comments re the margin on the abc test, so when it was £1.50 there was an 80p profit so cost 70p. Now it seems it is sold for £5.15 it no longer costs 70p but the cost of manufacture is closer to £3? As the commentators in the know reckon margin is 40%. One minor detail is that cost does not increase with price it is pretty much determined by raw materials and labour.

Max 18 business days to go, we know there are already updates for Annie’s note, so the longer we wait it probably means the potential of more incoming news, possibly a response to the latest NXP002 results.

CK said big things are happening just believe

What if Surescreen have had their contract and maybe receive another similar, but the 8bn contract is ODX and Gad. If it is a reverse of the RTC with ODX in the lead with Abingdon and BBI providing manufacturing support for ODX that would build the U.K. industry

And now the deal is back

Interesting the deal for 2.6p has been removed

PS or some great research where news not forthcoming keep digging so far it has been highest quality research

Agree soup sellers holding sp back. Last two deals showing on lse virtually covered the full quoted spread of over 8% that was a bit harsh on the buying price. At least at this level there are buyers getting a bargain. Moved over 1.6m sells yesterday so 30 trading days should be good need more news so holdings are cleared.

Random thought if Oxilio raise £20m their NAV will almost be double NFX.

There have now been 2 preclinical independent tests. As been said by a number of posters this drug is in the right space to assist combat a devastating illness which appears to also suffer the ravages of COVID-19. It should be attracting the interest of some serious players given the opportunity of speed to market. Inhaled therapy for a growing global problem.

I thought the news yesterday was outstanding the bottom line is NXP002 could effectively be given with every dose of treatment of pirfenidone or nintedanib. At least trading activity has picked up and there are buyers to feed the sells, more activity required which will happen as the news flow picks up.

That is current market for IPF not future and even at $6 per share for one drug not small when lot more in the portfolio

IPF market$2.5bn, NXP002 with SOC existing is huge.

IPF market is $2.5bn half of that market if NXP002 used with SOC drugs is wow

Interesting that Oxilio has a MoU with Biocopea which is a wholly owned subsidiary of Seek. Seek has a vertically integrated cannabis subsidiary called Provenance. As already mentioned Biocopea had a contract relationship with Sosei.

Looks like great news it would have to be Oxillo’s focus given they had a 6 months license limit. RNS is interesting;
“ in return for a significant upfront payment and additional development milestones and a royalty on net sales, capped at £2 million per annum”
One could argue the cap was disappointing but NFX total operating costs for 2020 was £1.5m so totally underwritten. The upfront payment could double the company NAV.

Larger margins on food tolerance and more space at Lilliport for more growth

More jobs
https://www.reed.co.uk/jobs/microarray-laboratory-scientist/42138766?source=searchResults#/jobs/omega-diagnostics-ltd/o633190?sortby=DisplayDate

Try this
“ Chief executive Colin King said the long-overdue move of the company’s food intolerance unit is now expected to take place in the final quarter of this year after delays to construction of a new 35,000sq ft purpose-built facility in Ely. This will become home to 65 of Omega’s 135 UK-based employees, with the others based out of the company’s Alva headquarters and Littleport facility in Cambridgeshire.”
https://www.heraldscotland.com/business_hq/18582438.omega-diagnostics-investors-crave-information/

I thought Lilliport was been replaced by the new facility at Ely but it looks as though in addition to
Conversation

Mike Edwards Man detective
@mike23edwards
#ODX move to Ely explained. It’s for the food intolerance side of the business. Which has higher margins! https://heraldscotland.com/business_hq/18582438.omega-diagnostics-investors-crave-information/…
Image